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Abstract
Background: Cancer stem cells (CSCs) play a key role in cancer initiation, progression and chemoresistance.
Epigenetic alterations have been identified as prominent factors that contribute to the CSCs phenotype. Here, we
investigated the effects of the HDAC inhibitor valproic acid (VPA) and the demethylating agent, 5’azacytidine (DAC)
on the stem phenotype of MG63 and Saos2 osteosarcoma cell lines.
Methods: Saos2 and MG63 cells were treated with DAC and VPA, alone and in combination. Untreated and treated
cells were examined for stemness phenotype by cytometry and real-time PCR. Sarcospheres and colonies formation
were also evaluated. Moreover, histone modification and methylation were tested by flow cytomery and western
blotting. HDAC2 depleted cells were examined for stemness phenotype and their ability to generate tumors in
NOD/SCID IL2R-gamma-0 (NSG) mice. HDAC2 expression on human osteosarcoma tissues was evaluated.
Results: We found that DAC and VPA induce an increased expression of stem markers including CD133, OCT4,
SOX2 and NANOG, and an increased ability in sarcospheres and colonies formation efficiency. Interestingly, we
showed that DAC and VPA treatment decreased repressive histone markers, while increased the active ones. These
histone modifications were also associated with an increase of acetylation of histones H3, a decrease of DNA global
methylation, HDAC2 and DNMT3a. Furthermore, HDAC2 silenced-MG63 and Saos2 cells acquired a stem phenotype,
and promoted in vivo tumorigenesis. In human osteosarcoma tissues, HDAC2 was strongly expressed in nucleus.
Conclusions: Collectively, our results suggest that VPA and DAC induce an expansion of osteosarcoma CSCs, and
we report for the first time that HDAC2 is a key factor regulating both CSCs phenotype and in vivo cancer growth.
In conclusion, we have identified HDAC2 as a potential therapeutic target in human osteosarcoma treatment.
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Background
Osteosarcoma is one of the most common pediatric
tumor in the world after leukemia. The prognosis is poor
with 65 and 20% 5-year survival rates for patients with
primary or metastatic tumors, respectively. At diagnosis,
distant metastases are found in 20% of patients and the
incidence of recurrence and metastasis following
primary treatment is very high [1, 2]. Although great
advances were made in the treatment of this disease,
benefits of current therapeutic strategies remain limited,
suggesting that new approaches are needed [3]. Osteosar-
coma may be considered a disease of osteoblastic differen-
tiation, since regulatory genes, involved in controlling the
differentiation of osteoblasts, may be silenced or de-regu-
lated [4]. This could be due to genetic and epigenetic dis-
orders of mesenchymal stem cells that differentiate into
osteoblasts [5]. Emerging evidences demonstrated that
osteosarcoma contains a subpopulation of cancer stem
cells (CSCs) [6–11]; we previously identified a stem
cell-like subpopulation expressing CD133 marker, that
was able to grow as sarcospheres and form tumors in
immunocompromised mice [10, 11].
Recent studies have indicated that specific epigenetic al-
terations such as DNA methylation and histone modifica-
tions could have a key role in generating the CSC
phenotype [12–16]. Epigenetic alterations could result in
the genesis of aberrant progenitor cells that undergo a
series of oncogenic mutations [17]. Therefore, changes in
DNA methylation and histones are an important feature of
tumor initiation and progression. For instance, these epi-
genetic modifications such as histone acetylation and DNA
methylation can regulate CD133 transcription [18, 19].
Baba et al. showed that ovarian CD133+ CSCs could be
epigenetically regulated leading to CD133 expression and
that it correlates with histones acetylation and DNA methy-
lation [19]. Osteosarcoma is characterized by a significant
genomic instability that could lead to a complete rearrange-
ment of a single chromosome and generation of new fusion
products [20, 21]. This could be due to interplays with
tumor microenvironment, host’s immune system and vas-
cular network that could encourage epigenetic alterations
[22–24]. Therefore, it is important to understand the in-
volvement of epigenetics in osteosarcoma initiation, since it
could be therapeutically reversible. Here, we examined the
epigenetic effects of the HDAC inhibitor valproic acid
(VPA) and the demethylating agent, 5-aza-2′-deoxycytidine
(DAC) on osteosarcoma cell lines. We found that
treatments with VPA and DAC promote the emergence of
a CSC population that is characterized by an epigenetic pat-
tern, where DNA hypomethylation, increase of H3 histone
acetylation, H3K4me2 and H3K4me3 and decrease of
H3K9me3, H3K27me3 and DNMT3a are observed. Finally,
knockdown experiments have identified HDAC2 as an es-
sential player in controlling osteosarcoma stemness and
tumorigenesis. Collectively, these results support a model
by which the modulation of HDAC2 and DNMT3a plays a
key role in generating and maintaining the cancer stem
phenotype in osteosarcoma.
Methods
Cell culture and treatments
Saos2 and MG63 osteosarcoma cell lines were purchased
from ATCC CELL BANK; cells were placed in DMEM
culture medium, supplemented with 10% FBS, 100 mM
2P-ascorbic acid, 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin (all purchased from Invitrogen,
San Giuliano Milanese, Milan, Italy) and placed in 25ml
flasks with filtered valves. Treatments with 5-aza-2′
-deoxycytidine (DAC) (Sigma Aldrich, Milan, Italy) and
valproic acid (VPA) (Sigma Aldrich), both diluted in
H2O, were administered at 3 μM and 0,5 mM, respec-
tively, and in combination replenishing them every 24 h
for 48 h.
MTT analyses
MTT assay (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylte
trazolium bromide) was used to measure the inhibition
of cell proliferation and to calculate the IC50. MTT was
added in cells exposed to either DAC or VPA at the
concentrations of 1,3,5, 10 and 100 μM at 48, 72 and 96
h for DAC and 0,5 and 1mM at 48, 72 and 96 h for
VPA. After identifying non-cytotoxic concentrations, we
performed an MTT assay to evaluate the combined
effect of both drugs at 48,72 and 96 h.
Four hours later, the formazan precipitate was
dissolved in 100 μL dimethyl sulfoxide, and then the
absorbance was measured in an ELISA reader (Thermo
Molecular Devices Co., Union City, USA) at 550 nm.
Growth analysis
Treated and untreated cells were plated at a density of
10 × 104 cells/well in 6-well plates. Cells were harvested
and re-suspended in PBS at 48, 72 and 96 h. An aliquot
of cell suspension was diluted with 0.4% trypan blue
(Sigma Aldrich), pipetted onto a haemocytometer and
counted under a microscope at 200x magnification. Live
cells excluded the dye, whereas dead cells admitted the
dye and consequently stained intensely with trypan blue.
The number of viable cells for each experimental condi-
tion was counted and represented on a linear graph.
Sarcospheres assay
Treated and untreated MG63 and Saos2 cells were
plated at a density of 6 × 104 cells/well in 6-well
ultra-low-attachment plates (Corning, Corning, NY,
USA) in DMEM/F12 cell medium supplemented with
progesterone (10 nM), putrescine (50 nM), sodium selenite
(15 nM), transferrin (13 ng/ml), insulin (10 ng/ml; Sigma,
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St. Louis, MO, USA), human EGF (10 ng/ml), and human
bFGF (10 ng/ml; Sigma Aldrich). Fresh aliquots of EGF and
bFGF were added every day. After 48–72 h from culture,
sarcospheres were visible with an inverted phase-contrast
microscope (TS 100; Nikon, Milan, Italy). The sarcosphere-
forming efficiency (SSFE) was calculated as the number of
sphere-like structures formed in 2 days divided by the ori-
ginal number of cells seeded and expressed as a percentage
(mean ± SD).
Flow cytometry
Treated and untreated cells were detached by trypsin,
counted and washed in 0.1% BSA in PBS. At least
500,000 cells were incubated with fluorescent-labeled
monoclonal antibodies or respective isotype controls
(1/10 diluted 4 °C for 30min in the dark). After washing
steps, the labeled cells were analyzed by flow cytometry
using a BD FACS Aria III (Becton & Dickinson, Mountain
View, CA, USA). The antibodies used were mouse
anti-human CD133/2 PE (Miltenyi Biotec S.r.l. Calderara
di Reno, Bologna, Italy), mouse anti-human CD29
PerCP-Cy5.5 (BD Pharmingen, Buccinasco, Milan, Italy),
mouse anti-human CD44 FITC (BD Pharmingen,
Buccinasco, Milan, Italy), and mouse anti-human CD324
PE (BD Pharmingen).
For intracellular and nuclear staining of vimentin,
osteocalcin, OCT4 PE, Sox2 FITC and Nanog
PerCP-Cy5.5, cells were processed using the Caltag Fix
& Perm Kit (Invitrogen, Milan, Italy) following the man-
ufacturer’s guidelines. Isotypes were used as controls. All
data were analyzed using a Diva software 6.6.
Histone modification and global DNA methylation
evaluation
Treated and untreated cells were detached by trypsin,
counted and washed in 0.1% BSA in PBS. At least
500,000 cells were stained using Caltag Fix & Perm Kit
(Invitrogen, Milan, Italy) following the manufacturer’s
guidelines with some modifications. Briefly, the cells
were fixed with medium A for 15min at room
temperature, washed with PBS and permeabilized with
0,5% triton X 100 for one hour at room temperature.
After washing steps, the cells were incubated with
medium B plus antibodies or respective isotype controls
for 1 h at room temperature. The primary antibodies
used were: H3trimethyl k9, H3acetyl k9, H3trimethyl
k27, H3trimethyl k4, and H3dimethyl k4, and HDAC2
antibodies, all purchased by Abcam. Total methylated
DNA was detected by immunolabeling with
anti-5-methylcytidine antibody (Abcam). This antibody
recognizes 5-methylcytidine, a modified base found in
the DNA of plants and vertebrates. It is specific to the
methylated base and has minimal reactivity to
non-methylated cytidine or cytosine. For staining, cells
were fixed with cold methanol for 10 min. After PBS
washing, cells were treated with 2 N HCL for 30 min at
37 °C, followed by an incubation of 5 min with 0,1M
borate buffer at pH 8,5. After washing steps, the cells
were incubated with medium B plus antibody or respect-
ive isotype controls for 1 h at room temperature.
Detection was performed by incubation with a
FITC-conjugated, affinity purified F(ab0)2 fragment of
goat anti-mouse or anti-rabbit IgG (Abcam, Cambridge,
UK) for 1 h at room temperature in the dark. The labeled
cells were analyzed by flow cytometry using a BD FACS
Aria III (Becton & Dickinson, Mountain View, CA, USA).
Histone modification and global DNA methylation associ-
ated to the cells was measured using FITC fluorochrome
and calculated as mean fluorescence intensity (MFI) for
each sample. The analyses are performed considering
100% untreated samples. 1 × 104 events were acquired and
histograms showed the mean ± SEM of the MFI values
obtained from three independent experiments.
Western blot assay
For Western blot analyses, cells were lysed in RIPA buffer
(50mM Tris-HCl pH 7.2, 150mM NaCl, 1% NP40, 0.1%
SDS, 0.5% DOC, 1mM PMSF, 25mMMgCl2, and supple-
mented with a phosphatase inhibitor cocktail). Protein
concentration was determined by the BCA assay (Bio-Rad
Laboratories, Hercules, CA). Equivalent amounts of pro-
tein (50 μg) were electrophoresed on 10% SDS–polyacryl-
amide gels. Precision Plus Protein™ Dual Color Standards
(Bio-Rad) was used to determine molecular weight. Gel
was electroblotted onto nitrocellulose membrane by using
a Trans Blot Turbo system (Bio-Rad) following the manu-
facturer’s instructions. The membrane was blocked with
5% milk in TBS-0.1% Tween (TTBS) for 1 h at RT and
washed with TTBS. Membrane was then incubated with
specific primary anti-human antibodies against HDAC1
(1:5000; Abcam), HDAC2 (1:1000; Abcam), DNMT1
(1:250; Abcam), DNMT3a (1:500; Abcam) or GAPDH
(1:5000; Millipore) over night at 4 °C. Total GAPDH anti-
body was used for assessing loading. Membrane was then
washed with TTBS and incubated with the appropriate
HRP-conjugated secondary antibody diluted 1:5000 in 3%
milk in TTBS for 1 h at RT. Membrane was then washed
three times with TTBS. Immunoreactive protein bands
were visualized by the Pierce™ ECL Western Blotting Sub-
strate (Thermo Scientific) according to the manufacturer’s
instructions. The densitometric analyses were performed
using Image J software and were expressed as ratio of
GAPDH densitometry versus tested protein densitometry.
Immunofluorescence
Treated and untreated cells were grown on coverslips
and fixed in methanol. Cells were permeabilized with 1%
TRITON X 100 in PBS and blocked using 1% BSA. Cells
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were stained with monoclonal anti-AcH3K9 (Abcam) and
corresponding IgG negative controls. Cells were subse-
quently stained with FITC rabbit anti mouse secondary
antibodies, counterstained with DAPI. Visualization was
performed using an EVOS microscope. Fluorescence
intensities from images of six randomly selected micro-
scopic fields of cells were semi-quantitatively analyzed by
densitometry using Image J software NIH Image.
Wound-healing assay
The wound-healing assay was performed to measure
two-dimensional movement. All cell fractions (untreated
or treated) were cultured in 24-well plates at a density of
50.000 cells/well until confluence. A wound was created
in the center of the cell monolayers by a sterile pipette tip.
The phase contrast images were captured after 0, 4, 24
and 48 h. The analyses are performed considering 100%
wound size at the time of culture and analyzed by Image J
software. All experiments were performed in triplicates.
Soft agar
To measure in vitro tumorigenicity due to drug treat-
ments, treated and untreated cells at a density of 500
cells per well in 24-well plates were plated in soft agar,
in triplicates. The test was performed using 0.8 and 0.3%
agar in DMEM as the base and top layers, respectively.
Cells were incubated for 21 days at 37 °C in a humidified
atmosphere at 5% CO2 in air, and 50ml of DMEM cul-
ture medium was added twice a week. At the end of the
incubation period, colonies were stained with nitroblue
tetrazolium (NBT, Sigma) at a concentration of 1 mg/2
ml in PBS and counted using an inverted microscope
(Nikon TS 100, Milan, Italy). The colony efficiency was
calculated as proportion of colonies per total number of
seeded cells. The data were analyzed by Image Pro Plus
software. All experiments were performed in triplicates.
Real-time q-PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen,
Milan, Italy) according to the manufacturer’s protocol.
RNA concentration and purity were determined by A260
and A260/A280 ratios, respectively. The integrity of total
RNA was assessed on standard 1% agarose/formaldehyde
gels. The RNA samples were treated with DNase I to
remove residual traces of DNA. Expression levels of genes
involved in angiogenesis were analyzed using real-time
quantitative PCR. All real-time PCR reactions were per-
formed using StepOne Thermocycler (Applied Biosystems,
Monza, Italy) and the amplifications were done using the
SYBR Green PCR Master Mix (Applied Biosystems,
Monza, Italy). The thermal cycling conditions were: 50 °C
for 2min followed by an initial denaturation step at 95 °C
for 2min, 40 cycles at 95 °C for 30s, 60 °C for 30s and 72 °C
for 30s. Real time q-PCR results were normalized to those
of the housekeeping gene glyceraldehyde-3-phospate de-
hydrogenase (GAPDH). The primer sequences were the
following (Additional file 1):
Sox2, 5-CGATGCCGACAAGAAAACTT-3 (sense)
and 5-CAAACTTCCTGCAAAGCTCC-3 (antisense);
Nanog, 5-TTCAGTCTGGACACTGGCTG-3 (sense)
and 5-CTCGCTGATTAGGCTCCAAC-3 (antisense);
OCT3/4, 5-ACATGTGTAAGCTGCGGCC-3 (sense)
and 5-GTTGTGCATAGTCGCTGCTTG-3 (antisense);
CD133, 5- ATGACAAGCCCATCACAACA-3 (sense)
and 5- CCTGAGTCACTACGTTGCCA-3 (antisense);
SLUG, 5-GAGCATTTGCAGACAGGTCA-3 (sense)
and 5-CCTCATTGTTTGTGCAGGAGA-3 (antisense);
OSTEOCALCIN, 5- CTCACACTCCTCGCCCTAT
TG-3 (sense) and 5-CTTGGACACAAAGGCTGCAC-3
(antisense);
TWIST, 5-TCTCGGTCTGGAGGATGGAG-3 (sense)
and 5-GTTATCCAGCTCCAGAGTCT-3 (antisense);
VIMENTIN, 5-CCTTGAACGCAAAGTGGAATC-3
(sense) and 5-GACATGCTGTTCCTGAATCTGAG-3
(antisense);
E-CADHERIN, 5-GGTCACAGCCACAGACGCGG-3
(sense) and 5- GGAAACTCTCTCGGTCCAGCCCA-3
(antisense);
GAPDH, 5-GGAGTCAACGGATTTGGTCG-3 (sense)
and 5-CTTCCCGTTCTCAGCCTTGA-3 (antisense).
Cell transfection
shHDAC2, and negative control shRNA (mock) neomycin
-resistant Sure Silencing shRNA plasmids were purchased
from SABioscience (Qiagen, Milano, Italy). The target
sequence used against human Hdac2 was as follows:
5’-TCAACCTAGTGCTGTGGTATT-3′. Negative control
shRNA sequence was: 5’-GGAATCTATTCGATGCATA
C-3′. MG63 and Saos2 cells were stably transfected with
these constructs in an Amaxa Nucleofector device with
the Amaxa Cell Line Nucleofector Kit V (Lonza GmbH,
Cologne, Germany) and according to the manufacturer’s
instructions. Clones with downregulated expression of
HDAC2 were selected with 500 μg/ml G418. Clones were
screened by flow cytometry and then analyzed for
stemness markers expression by flow cytometry,
sarcosphere-forming efficiency and in vitro tumorigenicity
assay by soft agar.
In vivo tumorigenicity by subcutaneous
xenotransplantation into NOD/SCID IL2R-gamma mice
Mock MG63 and HDAC2 depleted-MG63 cells were
injected subcutaneously into each flank of locally bred
NOD/SCID IL2R-gamma-0 (NSG) mice [25, 26].
For this purpose, cells were enzymatically dissociated,
diluted in PBS, mixed with Matrigel, and injected sub-
cutaneously in mice. Mice were monitored every 5 days
for the appearance of subcutaneous tumors. After 30
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days, mice were sacrificed, and the tumor volume was
calculated by the formula (l x w2)/2. The injection exper-
iments were made in triplicate. All mouse experiments
were performed according to the Institutional Animal
Care and Use Committee procedures and guidelines of
University of Campania.
Immunohistochemistry
Osteosarcoma paraffin-embedded tissue sections derived
from 20 human biopsies were obtained from archival
paraffin blocks. The sections were deparaffined and
rehydrated with xylene, a decreasing scale of alcohols
(100, 95, and 75°), and then distilled water. Immunohisto-
chemical analyses for HDAC2 (Abcam) were performed
with the Dako AEC kit, according to the manufacturer’s in-
structions. The nuclei were counterstained with
hematoxylin, and the samples were observed under an
inverted light microscope. The percentage of cells positive
or negative for HDAC2 was scored as follows: negative = 0,
positive staining < 10% = 1, positive staining ≥10 and < 33%
= 2, positive staining ≥33 and < 66%= 3, positive staining
≥66%= 4. Intensity of staining was scored on a scale of 0–3:
no color reaction = 0, mild reaction = 1, moderate reaction
= 2, and intense reaction = 3. Immunoreactive score (IRS)
was derived by multiplying immunoreactive cell scores and
intensity of staining scores to compute an immunoreactive
score ranging from 0 to 12.
Statistical analysis
Values are shown as the mean ± S.E.M. of measurements
of at least three independently performed experiments
to avoid possible variation of cell cultures. Student’s t
test was employed, and p < 0.05 was considered to be
statistically significant.
Results
Investigating the effect of DAC and VPA on survival and
growth of osteosarcoma cells using MTT assay
We investigate the possible epigenetic mechanism oc-
curring in osteosarcoma by treating Saos2 and MG63
cells with VPA and DAC, alone or in combination of
both. Therefore, we determined non-cytotoxic concen-
trations of both drugs using MTT and growth curve
evaluation. MTT analyses performed 48 h post-treatment
showed no significant differences in cell growth, while
after 72 h (and using different concentrations of both
drugs) there was high cytotoxicity. Furthermore, at
100 μM of DAC, cells were dead independently by treat-
ment length. The use of VPA concentration of 0.5 mM
up to 48 h did not induce differences in cell growth,
whereas 1 mM VPA reduced cell growth in a
time-dependent manner (Additional file 2). Cell growth
curves analyses were also performed, using the above
concentrations, without showing any statistically
significant differences in cell proliferation at 48 h
confirming data of MTT analyses (Additional file 2).
Moreover, the calculation of IC50 showed that, both for
Saos2 and MG63 cells, IC50 values were 10, 5 and 3 μM
for 48,72 and 96 h, respectively for DAC treatment, and
0,7, 0,6 and 0,1 mM for 48,72 and 96 h respectively for
VPA treatment. Being our aim that to evaluate the
epigenetic alterations occurring in osteosarcoma, we se-
lected the concentrations of 3 μM of DAC and 0,5 mM
of VPA and their combination for 48 h for all further
experiments.
Treatments with VPA, DAC or their combination increased
the expression of CD133, OCT4, SOX2 and NANOG in
osteosarcoma cells
To investigate the effect of DAC and VPA on osteosar-
coma stem cells, we analyzed different markers of stem-
ness by RT-PCR and flow cytometry. We performed a
gene expression analysis for OCT4, SOX2, NANOG and
CD133. Treatment of Saos2 cells with DAC induced an
increase of OCT4, SOX2 and CD133mRNA levels, but not
of NANOG mRNA level. On the contrary, treatment with
VPA induced an increase of NANOG, OCT4 and CD133
mRNA levels but not of SOX2 mRNA levels. The combin-
ation of both drugs induced a strong increase of OCT4
and CD133 mRNA levels. VPA and DAC treatment on
MG63 cells, another osteosarcoma cell line, induced an
increase of all stemness genes when compared to those of
untreated cells. Interestingly, drug combination led to a
strong increase of NANOG mRNA levels (Fig. 1a). Flow
cytometry analyses demonstrated that VPA and DAC in-
duced an increase of SOX2, OCT4 and NANOG proteins,
in both cell lines (Fig. 1b and Additional file 3). Remark-
ably, CD133 expression was increased after treatments
both in Saos2 and MG63 cell lines. In particular, both
VPA and DAC induced a considerable increase of CD133
expression and particularly in MG63 cells (Fig. 1c). The
combination of the two drugs resulted in almost 3-fold in-
crease of CD133 expression, when compared to untreated
cells. Treatment with VPA or DAC induced a two-fold
increase of CD133 expression and when compared to un-
treated cells (Additional file 4). In conclusion, DAC and
VPA induced an increase of stemness as reflected by
increased mRNA and protein levels of CD133, OCT4,
Sox2 and NANOG.
VPA, DAC treatments and their combination did not
induce changes in the expression of EMT-related markers
and in osteocalcin, CD29 and CD44 expression
VPA and DAC have been previously shown to induce
epithelial to mesenchymal transition (EMT) [27, 28]. It
has been shown that those transcription factors that in-
duce EMT in epithelial cells are involved, for example,
in drug resistance and other aggressiveness features of
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Fig. 1 Evaluation of stemness factors on Saos2 and MG63 cell lines after VPA and DAC treatment. (a) real-time PCR for SOX2, NANOG, OCT4 and
CD133 showing an increase of these genes after VPA and DAC treatments; (b) Flow cytometry analyses of increased expression of SOX2, OCT4
and NANOG in Saos2 and MG63 cells after VPA and DAC treatments; (c) up-regulation of CD133 on Saos2 and MG63 cells after VPA and DAC
treatments analysed by flow cytometry. * p < 0.005, ** p < 0.001, *** p < 0.0001 compared to the untreated cells
Noce et al. Journal of Experimental & Clinical Cancer Research          (2018) 37:296 Page 6 of 15
osteosarcoma [29]. Therefore, we determined the ex-
pression of SLUG, TWIST, vimentin, and e-cadherin,
osteocalcin, CD29 and CD44 by real-time PCR and flow
cytometry (Additional file 5).
VPA, DAC and their combination did not affect mRNA
expression levels of vimentin, whereas VPA alone induced
a strong increase of TWIST and e-cadherin mRNA levels
in both cell lines when compared to untreated cells. DAC
treatment led to a slightly increase of TWIST and a strong
up-regulation of e-cadherin mRNA levels.
Treatment combining VPA and DAC induced only a
strong increase of e-cadherin. Regarding to osteocalcin,
treatments induced a decrease of mRNA levels com-
pared to those of untreated cells (Additional file 5).
These results were partially confirmed by flow cytometry.
Although it was possible to observe an increase of vimentin
expression, this was not statistically significant in MG63
cells, whereas no change in its expression was detectable
for Saos2 cells (Additional file 5) which confirms our obser-
vations on mRNA levels. Moreover, flow cytometry analyses
showed that e-cadherin was undetectable in MG63 and
Saos2 cells (Additional file 5). Osteocalcin, CD29 and CD44
expressions were not affected by treatments (almost 90% of
expression). In summary and apart from inducing a slight
increase of TWIST, DAC and VPA did not affect EMT.
Similarly, no effect was observed for vimentin, osteocalcin,
CD29 and CD44 expression following treatments.
VPA, DAC alone and in combination increased
sarcospheres formation rate and colonies formation in
soft agar
Tumor stemness is also characterized by the ability to
form spheres and colonies in soft agar. Therefore, we cal-
culated the efficiency by which VPA and DAC induced
sarcospheres and colonies formation. Both drugs led to an
increase of sarcospheres formation rate, and when in
combination, the rate was 3-fold increased (Fig. 2a). One
method of analyzing the tumorigenic potential is the soft
agar assay, which measures anchorage-independent
growth. Assessment of growth kinetics revealed increased
efficiency in colony-forming ability of treated cells and
when compared to the untreated ones (Additional file 6).
In particular, the combination induced a strong effect with
a mean 3 fold-increase in colony-forming efficiency.
Another characteristic that correlates with stemness is mi-
gration ability. Wound healing experiments to measure
cell invasion revealed that both VPA and DAC enhanced
motility of Saos2 and MG63 cells when compared to un-
treated controls and for 24 h. In this context, VPA induced
a higher motility in MG63 compared to untreated and
DAC treated cells. On the other hand, in Saos2 cells,
drug combination increased cell migration, when
compared to untreated and single agent VPA or DAC
treated cells (Fig. 2b). Therefore, VPA, DAC and their
combination enhanced the in vitro migration of inves-
tigated osteosarcoma cell lines.
VPA, and DAC treatment affected histone modification
and DNA methylation
To explore the landscape of histone modifications and
DNA methylation that could be linked to our tumor
stemness model and in response to VPA and DAC treat-
ments, we performed an analysis of histone modifica-
tions that were previously shown to be involved in
embryonic stemness, such as the repressive histone
marks H3-trymethyl k9 (H3K9me3), H3-trymethyl k27
(H3K27me3), active histone marks H3-trymethyl k4
(H3K4me) and H3-dymethyl k4 (H3K4me2) [30]. More-
over, we investigated global epigenetic profiles of H3K9
acetylation and DNA methylation (Fig. 3). Flow cytome-
try analyses showed that VPA and DAC treatments,
alone and in combination, induced a decrease of
H3K9me3 and H3K27me3, and an increase of H3K4me2
and H3K4me3 (Fig. 3a). This indicates a correlation be-
tween those histone modifications and cancer stemness.
These data were further confirmed by H3K9 acetylation
and DNA methylation (Fig. 3). In fact, we found in-
creased levels of H3K9 acetylation (p < 0.001) in treated
cells, when compared with untreated cells (Fig. 3a). We
also observed a substantial increase of acetylation for
both cell lines when co-treated with VPA and DAC.
These results were confirmed by immunofluorescence
(Fig. 3b) semi-quantitatively analyzed by densitometry
(additional file 7) where we observed increased H3K9
acetylation in treated cells as reflected by elevated fluores-
cence using the AcH3K9 antibody and when compared to
untreated counterparts. Moreover, the levels of 5′ Methyl-
cytidine, analyzed by flow cytometry, showed a significant
reduction of global DNA methylation (p < 0.001) in treated
cells and when compared with untreated cells (Fig. 3c). To
better investigate this event, we performed a western blot-
ting for DNA methyltransferases 1 and 3a (DNMT1,
DNMT3a) that are the main enzymes involved in global
DNA methylation [31] (Fig. 4a). In Saos2 and MG63 cell
lines, DNMT1 expression did not change after drug treat-
ment, whereas DNMT3a expression severely decreased
(Fig. 4a). This is a very interesting finding, as it highlights
that DNMT3a could be a key factor involved in cancer
stemness in osteosarcoma carcinogenesis. VPA has been
suggested to inhibit the activity of histone deacetylases 1
and 2 (HDAC1, 2) [32]. Therefore, we investigated the
expression of the two enzymes after treatment in order to
investigate their possible role in cancer stem cells. Western
blotting analyses showed that in Saos2 and MG63 cell lines
HDAC1 expression did not change after treatment, there-
fore HDAC1 does not appear to be involved in acetylation
processes. However, HDAC2 levels decreased in both cell
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lines after treatment, mainly following VPA treatment and
drug combination (Fig. 4b).
HDAC2 knockdown promoted cancer stemness in
osteosarcoma and tumor growth in mouse xenografts
To confirm our results regarding the involvement of
HDAC2 in promoting cancer stemness, we performed a
silencing of HDAC2 using HDAC2 shRNA both in
MG63 (Fig. 5a) and Saos2 cells (Additional file 8).
HDAC2 depleted-MG63 and Saos2 cells showed an increase
of stemness markers CD133, OCT4, SOX2 and NANOG
when compared to control cells (Fig. 5b and Additional file
8). This result was comparable to that observed following
VPA and DAC treatments. Moreover, we found that HDAC2
depleted-MG63 and Saos2 cells had an increased H3K9
acetylation (Fig. 5c and Additional file 8) and a decreased
global DNA methylation (Fig. 5d and Additional file 8). This
observation also confirms the results obtained following VPA
and DAC treatments. Interestingly, an increase in sarco-
spheres (Fig. 5e and Additional file 8) and colonies formation
rates (Fig. 5f and Additional file 8) was also detectable for
HDAC2 depleted-MG63 and Saos2 cells and compared to
mock cells, which further supports the idea that HDAC2
Knockdown was effective in promoting stemness of osteosar-
coma cells (Fig. 5 and Additional file 8).
In addition, to investigate the in vivo effects of
HDAC2 downregulation on osteosarcoma tumorigenesis,
we injected knocked down HDAC2-MG63 cells in mice.
Fig. 2 Analyses of efficiency of forming sarcospheres, and wound healing assay on Saos2 and MG63 cell lines after VPA and DAC treatment. (a)
SSFE showing an increase of sarcospheres formation both in Saos2 and MG63cells after drug treatments; (b) Wound healing assay showing that
VPA and DAC a decrease of wound size in treated cells. * p < 0.005, ** p < 0.001, *** p < 0.0001 compared to the untreated cells
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We found that the HDAC2 downregulation significantly
promoted tumor growth in nude mice compared to
mock MG63 cells (Fig.6a) with a tumor size of 2,9 ± 0,5
fold greater than those detected in mock MG63 cells
(Fig. 6b). These results indicate that HDAC2 Knock-
down may promote the osteosarcoma tumorigenesis.
HDAC2 expression in human osteosarcoma biopsies
Immunohistochemical analyses of paraffin-embedded
tumor samples confirmed the presence of HDAC2 in
95% of cells and in all cases tested (Fig.7 a,b). In particu-
lar, HDAC2 was mainly expressed in nuclei of osteosar-
coma cells with an immunoreactive score > 7 (Fig.7b).
Fig. 3 Evaluation of histone modifications, acetylation and global methylation of DNA on Saos2 and MG63 cell lines after VPA and DAC
treatment. (a) Modulation of H3 trimethyl k9, H3 trimethyl k27, H3 trimethyl k4, H3 dimethyl k4 and H3 acetylation k9 by flow cytometry. VPA and
DAC induced a decrease of H3 trimethyl k9 and H3 trimethyl k27, and an increase of H3 trimethyl k4, H3 dimethyl k4 and H3 acetylation k9; (b)
Immunofluorescence for H3 acetylation k9 showing high levels of expression for VPA and DAC treatment; (c) Modulation of 5’methylcytidine
showing a decrease of its expression after VPA and DAC treatment using flow cytometry. ** p < 0.001, *** p < 0.0001 compared to the
untreated cells
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Although this, cytoplasmic localization was also found
and HDAC2 distribution was predominantly perinuclear
(Fig.7c). Also in this case, immunoreactive score was > 7.
Discussion
Osteosarcoma is a disease of differentiation characterized by
a variety of molecular and cytogenetic alterations, including
severe chromosomal rearrangements [30–33]. The loss of
differentiation is correlated with high grade osteosarcoma,
whereas a more differentiated phenotype is linked to low
grade osteosarcoma [34]. The mechanisms that are involved
in the correlation between aberrant differentiation and car-
cinogenesis and in the synergy between genetic and epigen-
etic processes might be decisive in maintaining osteosarcoma
cells in undifferentiated state. Several studies have shown that
DNA demethylation and the inhibition of HDACs induce
CSCs maintenance and may lead to reprogramming differen-
tiated cells into stem cells [19, 33, 34]. Here, we investigated
the epigenetic alterations occurring in osteosarcoma, treating
Saos2 and MG63 cells with DAC and VPA and identified a
possible molecular mechanism in stemness maintenance.
For this purpose, we examined stemness and EMT
related-markers expression, sarcospheres and colonies for-
mation efficiency, invasion abilities, global methylation status
and specific histone modifications. We demonstrated that
treating osteosarcoma cell lines with VPA and DAC pro-
motes the expression of the stem cell factors OCT4,
NANOG, SOX2 and CD133 [35, 36] and induces an increase
of the spheres and colonies formation efficiency, reinforcing
the idea that the said two substances are capable to maintain
the stemness phenotype.
Recent studies reported that VPA and DAC can also in-
duce EMT [27, 28]. In cancer, EMT enables cancer cells
to migrate and form metastasis by switching the pheno-
type from epithelial to mesenchymal profile [28, 37].
EMT, as well as, cancer stemness phenotype, is also char-
acterized by an increase of migratory and invasive abilities.
In osteosarcomas, it has been demonstrated that TWIST1
expression provides osteosarcoma cells resistance to
chemotherapy, whereas downregulation of SLUG induces
a decrease of migration [37, 38]. In our study, following
drug treatments, we observed that expression of vimentin,
CD44, CD29 and osteocalcin remained similar, the
e-cadherin levels were negative and the cell shape did not
change. Only Twist and SLUG mRNA levels increased.
Moreover, both drugs induced an increase of invasion
ability. All the above is in line with the so called “collective
cell migration phenomena” where cells do not undergo to
distinct and mutually exclusive morphological categories,
but rather they are a general continuum of morphological
variety which can be obtained combining diverse and
complementary mechanisms as previously proposed by
Campbell et al. in 2016 [39].
Having defined the stemness characteristics of
osteosarcoma cells in response to VPA and DAC
treatments, our interest was devoted to determine the
epigenetic events characterizing osteosarcoma CSCs.
Therefore, we investigated specific histone modifica-
tions and global DNA methylation. It is widely known
that the acetylation of histones H3 and H4 is mainly
associated with gene expression and the methylation
of H3 lysine 4, which recruits chromatin-remodeling
Fig. 4 Analyses of DNMT1, DNMT3a, HDAC1 and HDAC2 on Saos2 and MG63 cell lines after VPA and DAC treatment. (a) Western blotting for
DNMT1 and DNMT3a showing no change in the expression of DNMT1 and a decrease of DNMT3a expression; (b) Western blotting for HDAC1
and HDAC2 showing no change in the expression of HDAC1 and a decrease of HDAC2 expression. ** p < 0.001 compared to the untreated cells
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enzymes and leads to a relaxed or “open” chromatin
structure that is permissive to transcription [40]. On
the contrary, DNA methylation, trimethylation of H3
lysine 9 and lysine 27 elicits the compaction of chro-
matin leading to gene silencing [38]. Moreover, it has
been demonstrated that embryonic stem cells possess
the so-called bivalent domains of chromatin that
contains coextisting active (H3K4me3) and repressive
(H3K27me3) marks at promoters of specific genes in-
volved in the development [41, 42]. Notably, we
showed that repressive histone marks decreased and
active histone marks increased after drugs treatment.
These histone modifications were also associated with
an increase of acetylation of histones H3 and a
Fig. 5 Analyses of stemness on shHDAC2 MG63 cell line. (a) Flow cytometry analysis of HDAC2 expression in shHDAC2 MG63#1 and 2 cells and
MG63 mock after silencing; (b) Cytometric analysis of the expression of stemness factors in shHDAC2 MG63#1 and 2 cells showing a strong
increase of SOX2, OCT4, NANOG and CD133 stemness markers; (c) Flow cytometry showing elevated expression of H3 acetyl k9 on shHDAC2
MG63#1 and 2 cells compared to mock cells; (d) Decrease of DNA methylation of shHDAC2 MG63#1 and 2 cells; (e) SSFE showing an increase of
sarcospheres formation in shHDAC2 MG63#1 and 2 cells; (f) Soft agar assay showing increased ability to form colonies of shHDAC2 MG63#1 and
2 cells compared to those of mock cells. ** p < 0.001, *** p < 0.0001 compared to mock cells
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decrease of DNA global methylation. Therefore, here
we demonstrate, for the first time, that the stemness
profile of osteosarcoma cells is characterized by DNA
hypomethylation, increase of H3 histone acetylation,
H3K4me2 and H3K4me3 and decrease of H3K9me3
and H3K27me3. Histone modification and methyla-
tion status of DNA are dynamically orchestrated by
enzymes that remove or add covalent modifications to
histone proteins and CpG islands [30].
HDACs are enzymes that reduce the level of acetyl-
ation of core histones, repressing gene transcription [30]
and DNA methylation patterns are generated and main-
tained by the activity of specific enzymes: DNMTs [30].
Here, we investigate the effect of VPA and DAC on
HDAC1 and HDAC2 that usually are inhibited by VPA
and DNMT1 and DNMT3a that are targeted by DAC.
We observed that HDAC1 and DNMT1 expressions
remained similar independently by treatments indicating
that they have no key role in the processes of acetylation
and methylation in osteosarcoma. Conversely, we found
that VPA and DAC affected HDAC2 and DNMT3a ex-
pressions. Therefore, to reinforce our hypothesis, we
performed a HDAC2 silencing in MG63 and Saos2 cells
and investigated their stemness profile and their ability
to form new tumors in mice. Unfortunately, a silencing
also for DNMT3a cannot be performed because it highly
prevents osteosarcoma cells viability. MG63 and Saos2
shHDAC2 cells showed a stemness profile resembling to
the effect observed with drug treatments. In fact, the
lack of HDAC2 promoted an increase of Sox2, OCT4,
Nanog and CD133, a decrease of DNA methylation, an
increase of acetylation and colonies formation. More-
over, MG63 shHDAC2 cells were able to generate tu-
mors that grew faster and were greater than those
originating from mock MG63. In parallel, we investi-
gated HDAC2 expression in human osteosarcoma tis-
sues and we found that HDAC2 was expressed in all
cases and it was mainly localized in nucleus. Moreover,
some osteosarcomas cells showed also a cytoplasmic dis-
tribution of HDAC2 reinforcing our idea that HDAC2
alteration could be an important event in tumorigenesis
of osteosarcoma.
Then, we identify for the first time two enzymes,
HDAC2 and DNMT3a, that have a key role in maintain-
ing stemness status of osteosarcoma cells sustaining also
the tumor growth in vivo.
It is well known that histone modifications and DNA
methylation interact at multiple levels to regulate gene
Fig. 6 HDAC2 knowdown supported osteosarcoma tumorigenesis. (a) MG63 cells transfected with HDAC2 showed a tumor size grater than those
of mock MG63 cells; (b) evaluation of tumor volume derived from an injection of sh HDAC2 MG63 cells compared to those of mock MG63 cells
Data are presented as mean ± s.d. *** p < 0.0001 compared to mock cells
Fig. 7 Immuohistochemical staining for HDAC2 in human osteosarcoma tissues. (a) negative control; (b) nuclear staining of HDAC2 with
immunoreactive score of 12; (c); cytoplasmic staining of HDAC2 with immunoreactive score of 10
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expression status. In particular, DNMTs are able to re-
cruit HDACs achieving gene silencing and chromatin
condensation. For instance, it has been demonstrated
that DNA methylation can induce H3K9 methylation by
specific proteins, such as MeCP2, leading to a gene re-
pression [43–45]. In our study, we can hypothesize that
in normal conditions, HDAC2 can recruit DNMT3a
from cytosol to the nucleus. This complex can induce
gene repression, leading to a differentiated phenotype.
Conversely, a decrease of HDAC2 or DNMT3a expres-
sion or loss of both inhibits the formation of HDAC2/
DNMT3a complex leading to transcription of genes in-
volved in osteosarcoma stemness (Fig. 8). These prelim-
inary results suggest that targeting of HDAC2 could
have a strong potential therapeutic implication in the
treatment of human osteosarcoma.
Conclusions
In summary, our preliminary study highlights peculiar fea-
tures of osteosarcoma CSCs biology as follows: i. VPA and
DAC induce an expansion of CSCs; ii. epigenetic pattern
of such cells is characterized by DNA hypomethylation,
increase of H3 histone acetylation, H3K4me2 and
H3K4me3 and decrease of H3K9me3 and H3K27me3; iii.
HDAC2 and DNMT3a are key enzymes in generating can-
cer stem phenotype in osteosarcoma; iv. induction of
HDAC2 expression could have a strong potential thera-
peutic implication. Therefore, our study identifies, for the
first time, specific epigenetic events that maintain cells in
undifferentiated state. This is crucial in osteosarcoma
treatment since the identification of specific epigenetic
defects can support the design of better therapeutic strat-
egies leading to the development of target epigenetic
drugs. Therefore, the combination of epigenetic thera-
peutic approaches with standard chemotherapy could be a
promising strategy for successful treatment of osteosar-
coma. Moreover, these approaches show the advantage to
sensitize cancer cells, in particular cancer stem cells, that
are refractory to standard chemotherapy.
Additional files
Additional file 1: Table S1. Primer sequences. (DOC 34 kb)
Additional file 2: Figure S1. Evaluation of on Saos2 and MG63 cells
viability after VPA and DAC treatment. (a) MTT assay showing effect of
VPA and DAC on Saos2 and MG63 cells; (b) Growth curves of
osteosarcoma cells after drug treatments. (TIF 16532 kb)
Additional file 3: Table S2. Distribution of Sox2, OCT4 and Nanog
stemness markers in Saos2 and MG63 cells after drug treatments. (DOC
32 kb)
Additional file 4: Figure S2. Evaluation of CD133 marker on Saos2 and
MG63 cell lines after VPA and DAC treatment. Flow cytometric analyses
showed a strong increase of CD133 expression after drug treatments. **
p < 0.001, *** p < 0.0001 compared to the untreated cells. (TIF 242 kb)
Additional file 5: Figure S3. Analyses of EMT related markers on Saos2
and MG63 cell lines after VPA and DAC treatment. (a) Real-time PCR for
SLUG, TWIST, Vimentin E-cadherin and Osteocalcin showing an increase
of SLUG mRNA levels in MG63 and Saos2 cells following VPA and com-
bination treatment, a strong increase of TWIST mRNA levels in both cell
lines following VPA treatment and an increase of E-cadherin mRNA after
DAC treatments. Vimentin mRNA levels did not change. Osteocalcin mRNA
levels decreased in both cell lines; (b) Expression of CD324, vimentin and
osteocalcin in Saos2 and MG63 cell lines after VPA and DAC treatment ana-
lysed by flow cytometry. CD324, Vimentin and Osteocalcin did not change
after drug treatment compared to untreated cells. * p < 0.005, ** p < 0.001,
*** p < 0.0001 compared to the untreated cells. (TIF 8966 kb)
Fig. 8 Proposed mechanistic model of HDAC2 function in osteosarcoma. Decrease of HDAC2 or DNMT3a expression or loss of both inhibits the
formation of HDAC2/DNMT3a complex leading to transcription of genes involved in osteosarcomas stemness and promoting tumor initiation
and progression
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Additional file 6: Table S3. Primary colony-forming efficiency of treated
versus untreated cells in Saos2 and MG63 cell lines. (DOC 36 kb)
Additional file 7: Fluorescence evaluation. Densitometry analyzing
semi-quantitatively fluorescence for H3 acetylation k9. Data showed high
levels of expression following VPA and DAC treatments. (TIF 147 kb)
Additional file 8: Analyses of stemness on shHDAC2 Saos2 cell line. (a)
Cytometric analysis of HDAC2 expression in shHDAC2 Saos2#1 cells and
mock after silencing; (b) strong increase of SOX2, OCT4, NANOG and
CD133 stemness markers expression in shHDAC2 Saos2#1 cells by flow
cytometry; (c) elevated expression of H3 acetyl k9 on shHDAC2 Saos2#1
cells by flow cytometry; (d) decrease of DNA methylation of shHDAC2
Saos2#1 cells; (e) SSFE showing an increase of sarcospheres formation in
shHDAC2 Saos2#1 cells; (f) Soft agar assay showing increased ability to
form colonies of shHDAC2 Saos2#1 cells compared to those of mock
cells. ** p < 0.001, *** p < 0.0001 compared to mock cells. (TIF 17257 kb)
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